These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24522405)

  • 1. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
    Kitagawa Y; Ueno S; Izumi K; Mizokami A; Hinotsu S; Akaza H; Namiki M
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):673-9. PubMed ID: 24522405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
    Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
    Sasaki T; Onishi T; Hoshina A
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.
    Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
    BMC Urol; 2014 Apr; 14():33. PubMed ID: 24773608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.
    Hori S; Jabbar T; Kachroo N; Vasconcelos JC; Robson CN; Gnanapragasam VJ
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):235-41. PubMed ID: 20390426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.
    Sasaki T; Onishi T; Hoshina A
    Endocr Relat Cancer; 2012 Oct; 19(5):725-30. PubMed ID: 22807499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
    Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
    Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
    Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
    World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
    Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy.
    Zhenhao Z; Xiaofeng C; Hao J; Ming Y; Hongtao Z; Wenrui H; Cheng Z; Xiaochen Z; Gongxian W
    Cancer Med; 2022 Sep; 11(17):3251-3259. PubMed ID: 35307955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
    Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
    BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
    Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
    Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J
    Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.
    Pike LRG; Wu J; Chen MH; Loffredo M; Renshaw AA; Pfail J; Kantoff PW; D'Amico AV
    Urology; 2019 Apr; 126():145-151. PubMed ID: 30664895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
    Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
    Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
    Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
    Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level.
    Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e65-e71. PubMed ID: 25471685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.